Common use of Grant-Back License Clause in Contracts

Grant-Back License. COMPANY agrees to grant to CRUCELL a non-exclusive license, with the right to sub-license as provided in this Section 2.2, to any and all PATENTS owned and/or controlled by COMPANY, claiming, and know-how related to, inventions made and/or conceived during the course of, and/or resulting from, activities performed under the licenses in Section 2.1, which inventions relate to and cover the production of VIRAL PARTICLES using PER.C6® CELLS and/or the use, and/or optimization of operating parameters relating to PER.C6® CELLS. To the extent that such PATENTS or know-how extend to cells other than PER.C6® CELLS, CRUCELL’s license right under this clause shall be limited to adenoviral E1-immortalized human cell lines, and the use of, handling of or manufacture thereof, and CRUCELL’S rights shall not extend to the use or sale of the particular VIRAL PARTICLES that are developed by VAXIN and or that are the subject of the licenses under Section 2.1. CRUCELL shall only sublicense its rights under this clause to existing and future licensees under the PER.C6® CELL PATENTS and/or PER.C6® CELL KNOW HOW, which licensees grant to CRUCELL a grant-back license to improvements on substantially the same terms as granted herein, which terms provide for the sublicensing of such improvements to other PER.C6® licensees including VAXIN.

Appears in 2 contracts

Samples: Second Restated License Agreement, Second Restated License Agreement (Altimmune, Inc.)

AutoNDA by SimpleDocs

Grant-Back License. COMPANY agrees VAXIN and its REGISTERED AFFILIATES hereby agree to grant to CRUCELL a non-exclusive license, with the right to sub-license as provided in this Section 2.2, to any and all PATENTS owned and/or controlled by COMPANYVAXIN and/or REGISTERED AFFILIATES, claiming, and know-how related to, inventions made and/or conceived during the course of, and/or resulting from, activities performed under the licenses in Section 2.1, which inventions relate to and cover the production of VIRAL PARTICLES using PER.C6® CELLS and/or the use, and/or optimization of operating parameters relating to PER.C6® CELLS. To the extent that such PATENTS or know-how extend to cells other than PER.C6® CELLS, CRUCELL’s license right under this clause shall be limited to adenoviral E1-immortalized human cell lines, PER.C6® CELLS and the use of, handling of or manufacture thereof, and CRUCELL’S rights shall not extend to the use or sale of the particular VIRAL PARTICLES that are developed by VAXIN and or that are the subject of the licenses under Section 2.1. CRUCELL shall only sublicense its rights under this clause to existing and future licensees under the PER.C6® CELL PATENTS and/or PER.C6® CELL KNOW HOW, which licensees grant to CRUCELL a grant-back license to improvements on substantially the same terms as granted herein, which terms provide for the sublicensing of such improvements to other PER.C6® licensees including VAXIN.

Appears in 2 contracts

Samples: Second Restated License Agreement, Second Restated License Agreement (Altimmune, Inc.)

AutoNDA by SimpleDocs

Grant-Back License. COMPANY agrees to grant VAXIN grants to CRUCELL a an irrevocable, non-exclusive, sublicensable license, to PER.C6 KNOW-HOW controlled by VAXIN. VAXIN grants to CRUCELL an irrevocable, non-exclusive license, with the right to sub-license as provided in this Section 2.2sublicense, to any and all PATENTS owned and/or controlled by COMPANY, claiming, and know-how controlled by VAXIN and claiming (for PATENTS) or related to, to (for know-how) inventions made and/or or conceived during the course of, and/or or resulting from, activities performed under the licenses license in Section 2.1, which inventions relate to and cover the production of VIRAL PARTICLES using PER.C6® CELLS and/or the use, and/or optimization of operating parameters relating to PER.C6® CELLS. To the extent that such PATENTS or know-how extend to cells other than PER.C6® CELLS, CRUCELL’s license right under this clause shall be limited to adenoviral E1-immortalized human cell lines, PER.C6® CELLS and the use of, handling of or manufacture thereof, and CRUCELL’S ’s rights shall not extend to the use or sale of the particular VIRAL PARTICLES that are developed by VAXIN and or and/or that are the subject of to the licenses under Section 2.1. CRUCELL shall only sublicense its rights under this clause to existing and future licensees under the of PER.C6® CELL PATENTS and/or or PER.C6® CELL KNOW HOW, which licensees grant to CRUCELL a grant-back license to improvements on substantially the same terms as granted herein, which terms provide for the sublicensing of such improvements to other PER.C6® licensees including VAXINlicensees.

Appears in 1 contract

Samples: License Agreement (Altimmune, Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.